𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of Mitonafide in advanced and relapsed colorectal cancer

✍ Scribed by Albert Abad; Cristina Grávalos; Albert Font; Francisco Molina; María Teresa Díaz-Puente; Xavier Fabregat; Ana Benavides; Miguel Martin

Publisher
Springer US
Year
1996
Tongue
English
Weight
201 KB
Volume
14
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I-II study of ftorafur and methyl-
Phase I-II study of ftorafur and methyl-ccnu in advanced colorectal cancer
✍ Robert J. Belt; Ronald Stephens 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 2 views

The combination of Ftorafur (NSC-148958) and methyl-CCNU (NSC-95441) was evaluated in 36 patients with advanced colorectal cancer. The principle toxicities encountered were myelosuppression, gastrointestinal, and neurological. There were no complete responses and only 5/34 (14.7%) patients achieved

A phase II study of sequential methotrex
A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer
✍ L. Panasci; J. Ford; R. Margolese 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 242 KB

Twenty-nine patients with advanced colorectal cancer were treated with methotrexate (MTX) 200 mg/m2 followed 1 h later by fluorouracil (FU) (1000 mg/m2) and 24 h later by oral leucovorin 20 mg every 6 h for six doses. The cycle was repeated every 2 weeks. Among the 25 evaluable patients there were 2

Phase II trial of menogaril in advanced
Phase II trial of menogaril in advanced colorectal cancer
✍ Eduard E. Holdener; Wim W. Bokkel Huinink; Genevieve Decoster; Christian Ludwig; 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 262 KB

Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were ach